All GLG News Analyses Filed Under: Ophthalmology

In a study of patients with choroidal neovascularization due to age-related macular degeneration, Lazic and Gabric demonstrated that improvements in vision and reduction of central macular thickness after one month and their maintenance over three months are more significant after verteporfin photodynamic...

A study reported in the March issue of Archives of Ophthalmology describes a new intravitreous drug delivery system for treating persistent retinal macular swelling. Using dexamethasone DDS and appropriate follow up, patients with this new system had significantly improved vision and and safety mea...

Tahzib et al. conducted a 10-year retrospective follow-up study of the Artisan phakic intraocular lens (PIOL) for the correction of moderate to high nearsigtedness and concluded the device is both stable and predictable, but only when strict inclusion criteria are used. Over 90% of patients achieved...

• SurModics presented the next generation of I-vation(TM) at the Boston Ocular Anti-Angiogenesis conference in April 2007.  • In laymans terms, I-vation is a sort of "screw" that is administered via a proprietary "surgical drill." • If this technology is eventually approved...

Surmodics and Merck agree to work together that could greatly benefit both companies.  For Merck, they will have access to a novel ocular drug delivery system that would expose them to expanding areas of retinal disease.  For Surmodics, they gain Merck's backing and glaucoma and retina medications...

This survey from the 2006 survey of members of the American Society of Cataract and Refractive Surgery highlights  emerging trends  in  refractive surgery showing large increases in wavefront, LASEK, and Phakic IOLS.  There was a smaller increase in Intralase.  Refractive surgery...

At the a keynote lecture at the Pan-American Association of Ophthalmology meeting, there is talk about the exciting new intraocular therapies.  Much of this excitement has been generated with the use of Anti-Vegf agents (Macugen, Genetech) for retinal disease; and now those ideas are being applied...

Laser eye-treatment company TLC Vision Corp. said it agreed to sell all the common shares of OccuLogix Inc. to JEGC OCC Corp which is owned by a private equity firm.  Occulogix has some emerging therapies in different areas of eye care including Age Related Macular Degeneration and Glaucoma. ...

The VEGF Trap from Regeneron is a protein made up off human VEGF receptors fused to human immunoglobulin. This compound binds VEGF, preventing VEGF from binding to its natural receptors, interrupting the angiogenic cascade. The phase II study presented at 2007 ARVO showed promising results in patients...

At the recent ARVO meeting, Italian researchers performing a randomized clinical trial on patients with wet AMD found that patients treated with photodynamic therapy (PDT) with Visudyne (verteporfin, Novartis) plus Lucentis(ranibizumab, Genentech) had a better visual result than patients treated with...